Geode Capital Management LLC lifted its position in Evolus, Inc. (NASDAQ:EOLS – Free Report) by 0.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,210,621 shares of the company’s stock after buying an additional 11,027 shares during the period. Geode Capital Management LLC owned about 1.91% of Evolus worth $19,616,000 as of its most recent SEC filing.
A number of other institutional investors have also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. lifted its holdings in shares of Evolus by 173.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 418,576 shares of the company’s stock valued at $6,781,000 after purchasing an additional 265,635 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Evolus by 24.6% during the second quarter. Bank of New York Mellon Corp now owns 181,093 shares of the company’s stock valued at $1,965,000 after purchasing an additional 35,760 shares during the last quarter. Armistice Capital LLC bought a new position in Evolus during the second quarter valued at approximately $3,906,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Evolus during the third quarter valued at $940,000. Finally, Rice Hall James & Associates LLC lifted its holdings in Evolus by 6.3% in the third quarter. Rice Hall James & Associates LLC now owns 904,900 shares of the company’s stock valued at $14,659,000 after acquiring an additional 53,605 shares during the period. Hedge funds and other institutional investors own 90.69% of the company’s stock.
Evolus Stock Performance
Shares of NASDAQ EOLS opened at $11.09 on Friday. The firm’s fifty day moving average is $13.35 and its two-hundred day moving average is $13.73. Evolus, Inc. has a 52-week low of $9.80 and a 52-week high of $17.82. The company has a market cap of $702.23 million, a P/E ratio of -12.19 and a beta of 1.27. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47.
Analyst Upgrades and Downgrades
Read Our Latest Report on Evolus
About Evolus
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
See Also
- Five stocks we like better than Evolus
- How to Use the MarketBeat Stock Screener
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
- Trading Stocks: RSI and Why it’s Useful
- Top 3 ETFs to Hedge Against Inflation in 2025
- What is the Shanghai Stock Exchange Composite Index?
- These 3 Chip Stock Kings Are Still Buys for 2025
Want to see what other hedge funds are holding EOLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolus, Inc. (NASDAQ:EOLS – Free Report).
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.